Name: RO 7105705
Synonyms: RG 6100
Therapy Type: Immunotherapy (passive) (timeline)
Target Type: Tau (timeline)
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Phase 1)
Company: AC Immune SA, Genentech, Hoffmann-La Roche
This is an anti-tau antibody that grew out of a research collaboration between AC Immune and Genentech, part of the Roche Group. No preclinical data has been published specifically on an investigational therapeutic by this name; however, the AC Immune/Genentech collaboration has focused on approaches that target extracellular, not intracellular, tau. The aim was to explore antibodies with reduced effector function in an effort to limit microglial activation leading to inflammatory responses (e.g., Lee et al., 2016).
In July 2016, Genentech/Roche Group began enrolling for a first Phase 1 study of 71 volunteers comprising both healthy controls and people with mild to moderate Alzheimer's disease. Conducted in Tennessee, this trial compares the antibody to placebo on safety, tolerability, pharmacokinetics, and preliminary activity outcomes. The trial design combines single dose, dose-escalation, and multiple dosing. The study is expected to run until May 2017.
For details, see clinicaltrials.gov.
- Lee SH, Le Pichon CE, Adolfsson O, Gafner V, Pihlgren M, Lin H, Solanoy H, Brendza R, Ngu H, Foreman O, Chan R, Ernst JA, DiCara D, Hotzel I, Srinivasan K, Hansen DV, Atwal J, Lu Y, Bumbaca D, Pfeifer A, Watts RJ, Muhs A, Scearce-Levie K, Ayalon G. Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement. Cell Rep. 2016 Aug 9;16(6):1690-700. Epub 2016 Jul 28 PubMed.
No Available Further Reading